Achieve Life Sciences stock analysis
Achieve Life Sciences (SP4P) Stock Price & Analysis
SP4P Stock Chart & Stats
- Day’s Range
- EUR 5.35 - EUR 5.35
- 52-Week Range
- EUR 2.29 - EUR 7.25
- Previous Close
- EUR 5.50
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 555.56M
- Enterprise Value
- EUR 665.84M
- Total Cash (Recent Filing)
- EUR 201.52M
- Total Debt (Recent Filing)
- EUR 13.76M
- Price to Earnings (P/E)
- ―
- Beta
- 1.47
- Next Earnings
- Mar 11, 2027 (Est.)
- EPS Estimate
- -0.18
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Focused Smoking-cessation Pipeline
A focused lead program targeting nicotine dependence gives Achieve Life Sciences a clear strategic direction and addresses a defined public-health need. If development and approval succeed, cytisinicline could support a specialized prescription-product business rather than a diversified but unfocused pipeline.
Regulatory And Launch Preparation
Preparation for NDA resubmission and a planned commercial launch indicate progress toward converting the company from a development-stage operation into a potential prescription-product business. This creates a pathway to future revenue and broader operating leverage, although approval remains necessary.
Manageable Debt And Equity Cushion
Manageable absolute debt and a sizable equity balance provide some financial capacity to continue research and development while the lead product remains investigational. This cushion may reduce immediate balance-sheet pressure, although it does not eliminate the need for funding while losses continue.
Bears Say
Minimal Revenue And Severe Losses
The company has not yet demonstrated a functioning commercial revenue base, while losses are extremely large relative to reported sales. Persistent negative profitability leaves the business dependent on successful clinical and regulatory execution before meaningful operating leverage can emerge.
Persistent Cash Burn
Sustained negative operating and free cash flow means the company consumes capital to fund its operations and development programs rather than generating internal funding. Continued or increasing burn can shorten financial flexibility and raise the need for additional capital before commercialization.
Dependence On External Financing
Because the investigational product has not established commercial sales, ongoing operations rely on financing activities and external capital. This dependence can constrain strategic flexibility and expose shareholders to dilution or unfavorable financing terms if losses persist.
Achieve Life Sciences News
SP4P FAQ
What was Achieve Life Sciences’s price range in the past 12 months?
What is Achieve Life Sciences’s market cap?
When is Achieve Life Sciences’s upcoming earnings report date?
How were Achieve Life Sciences’s earnings last quarter?
Is Achieve Life Sciences overvalued?
Does Achieve Life Sciences pay dividends?
What is Achieve Life Sciences’s EPS estimate?
How many shares outstanding does Achieve Life Sciences have?
What happened to Achieve Life Sciences’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Achieve Life Sciences?
What is the TipRanks Smart Score and how is it calculated?
Achieve Life Sciences Stock Smart Score
Company Description
Achieve Life Sciences
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Bothell, WA.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Andrew D. Goldberg
- Employees
- 28
- Website
- www.achievelifesciences.com
- Address
- 22722 29th Dr. SE, Bothell, WA, 98021, US
Achieve Life Sciences (SP4P) Earnings & Revenues
SP4P Earnings Call
Earnings Call SentimentPositive
The call conveyed strong positive momentum: a substantial financing, experienced new leadership and commercial hires, U.S. manufacturing partnership with initial batches, robust Phase III efficacy (notably 32.4% vs 6% in hard-to-treat patients) and supportive mechanistic/tolerability data. The principal negatives are an anticipated FDA CRL tied to a third-party manufacturer OAI, requiring an NDA resubmission in Q4 2026 and introducing execution risk around the manufacturing tech transfer to Adare and timing uncertainty. Overall, the company appears well capitalized and operationally proactive to address the delays and pursue a planned H1 2027 launch, but near-term regulatory and manufacturing execution risks remain.
View all DE:SP4P earnings summariesSP4P Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 1 | 13 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 2 | 0 | 10 |












